Pharvaris N.V. (PHVS) vs Spyre Therapeutics (SYRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Spyre Therapeutics (SYRE) has outperformed Pharvaris N.V. (PHVS) over the past year, gaining 304.8% versus a gain of 36.2%. Over five years, PHVS leads with a +96.8% price change compared with -58.1% for SYRE. Spyre Therapeutics is the larger company by market cap ($7.91 billion vs $2.18 billion), about 3.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PHVS | SYRE |
|---|---|---|
| Share price | $31.10 | $85.69 |
| Market cap | $2.18B | $7.91B |
| 1-day change | -0.06% | +7.25% |
| YTD return | +12.07% | +161.57% |
| 1-year return | +36.16% | +304.77% |
| 5-year return | +96.84% | -58.10% |
| EPS (TTM) | $-3.06 | $-1.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Net income (latest FY) | $-25.99M | $-155.20M |
| 52-week high | $43.25 | $110.18 |
| 52-week low | $20.65 | $18.12 |
| Distance from 52-week high | -28.09% | -22.22% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +84.47% | +40.28% |
| Average volume | 711.75K | 1.22M |
| Shares outstanding | 70.20M | 92.29M |
| Employees | 148 | 125 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Spyre Therapeutics is about 3.6 times larger than Pharvaris N.V. by market value ($7.91B vs $2.18B).
- SYRE has outperformed PHVS by 268.6 percentage points over the past year.
About Pharvaris N.V.
PHVS stock →Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant.
Healthcare · Biotechnology · 148 employees
About Spyre Therapeutics
SYRE stock →Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A).
Healthcare · Biotechnology · 125 employees
PHVS vs SYRE FAQ
Which is bigger, Pharvaris N.V. or Spyre Therapeutics?
Spyre Therapeutics (SYRE) is larger, with a market capitalization of $7.91B compared with $2.18B for Pharvaris N.V. (PHVS).
Which stock has performed better over the past year, PHVS or SYRE?
SYRE returned +304.77% over the past 12 months, compared with +36.16% for PHVS (price return, excluding dividends). Past performance does not predict future results.
Are Pharvaris N.V. and Spyre Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.